CCR2 Involved in Removing Beta-Amyloid, Could Slow Alzheimer’s Progression

First study to suggest that the immune system may protect against Alzheimer’s changes in humans

Recent work in mice suggested that the immune system is involved in removing beta-amyloid, the main Alzheimer’s-causing substance in the brain. Researchers have now shown for the first time that this may apply in humans.

Researchers at the Peninsula College of Medicine and Dentistry, University of Exeter with colleagues in the National Institute on Aging in the USA and in Italy screened the expression levels of thousands of genes in blood samples from nearly 700 people. The telltale marker of immune system activity against beta-amyloid, a gene called CCR2, emerged as the top marker associated with memory in people.

The team used a common clinical measure called the Mini Mental State Examination to measure memory and other cognitive functions.

Structure of protein CCR2.

CCR2 might protect against Alzheimer's changes, a new study claims. Image adapted from Wikimedia Commons user Pleiotrope.

The previous work in mice showed that augmenting the CCR2-activated part of the immune system in the blood stream resulted in improved memory and functioning in mice susceptible to Alzheimer’s disease.

Professor David Melzer, who led the work, commented: “This is a very exciting result. It may be that CCR2-associated immunity could be strengthened in humans to slow Alzheimer’s disease, but much more work will be needed to ensure that this approach is safe and effective”.

Dr Lorna Harries, co-author, commented: “Identification of a key player in the interface between immune function and cognitive ability may help us to gain a better understanding of the disease processes involved in Alzheimer’s disease and related disorders.”

Alzheimer’s disease is the most common form of dementia and affects around 496,000 people in the UK.

About this Alzheimer’s research

The Peninsula College of Medicine and Dentistry is a joint entity of the University of Exeter, Plymouth University and the NHS in the South West of England. PCMD has created for itself an excellent national and international reputation for groundbreaking research in the areas of diabetes and obesity, neurological disease, child development and ageing, dentistry, clinical education and health technology assessment.

Contact: Andrew Gould – University of Exeter
Source: Peninsula College of Medicine and Dentistry
Image Source: Neuroscience image adapted from Wikimedia Commons user Pleiotrope. Image licensed under public domain.
Original Research: Abstract for “Leukocyte CCR2 Expression Is Associated with Mini-Mental State Examination Score in Older Adults” by Lorna W. Harries, Rachel M. Bradley-Smith, David J. Llewellyn, Luke C. Pilling, Alexander Fellows, William Henley, Dena Hernandez, Jack M. Guralnik, Stefania Bandinelli, Andrew Singleton, Luigi Ferrucci, and David Melzer. Published in Rejuvenation Research 2012, ahead of print. doi:10.1089/rej.2011.1302.
Research cited in this article: Full research paper (PDF) for “Hematopoietic CC-Chemokine Receptor 2 (CCR2) Competent Cells Are Protective for the Cognitive Impairments and Amyloid Pathology in a Transgenic Mouse Model of Alzheimer’s Disease” by Gaëlle Naert and Serge Rivest. Published in Molecular Medicine 18 : 297 – 313 , 2012 doi: 10.2119/molmed.2011.00306.

Join our Newsletter
I agree to have my personal information transferred to AWeber for Neuroscience Newsletter ( more information )
Sign up to receive the latest neuroscience headlines and summaries sent to your email daily from NeuroscienceNews.com
We hate spam and only use your email to contact you about newsletters. We do not sell email addresses. You can cancel your subscription any time.